trending Market Intelligence /marketintelligence/en/news-insights/trending/sEzVFKEJJgsGNawCxpVTYw2 content esgSubNav
In This List

Biotechnology company Inhibrx plans IPO on Nasdaq

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Biotechnology company Inhibrx plans IPO on Nasdaq

Inhibrx Inc. filed for an IPO of up to $74.8 million of its common stock on the Nasdaq Global Market.

The La Jolla, Calif.-based biotechnology company is planning to list its common stock on the bourse under the ticker INBX.

Inhibrx will also sell its common stock of about $10 million to Italy's Chiesi Farmaceutici SpA at the issue price per share equal to the IPO price in a separate private placement.

The company, which is focused on developing novel biologic therapeutic candidates, plans to use the proceeds from the offerings to complete three phase 1 studies for drugs targeting cancers and rare diseases.

Inhibrx said that INBRX-109 is being evaluated in patients with solid tumors including sarcomas, INBRX-105 is being studied as potential treatment for PD-L1 expressing tumors, while INBRX-101 will be evaluated as a potential treatment for rare respiratory disease alpha-1 antitrypsin deficiency, or AATD.

The company licensed its worldwide rights for INBRX-103 therapeutic candidate to Celgene Corp. and optioned development and commercialization rights for INBRX-101 therapeutic candidate outside of the U.S. and Canada to Chiesi Farmaceutici.

Inhibrx will use the remaining proceeds for research and development activities, as well as for working capital and other general corporate purposes.

Evercore Group LLC, Barclays Capital Inc., Nomura Securities International Inc. and Raymond James & Associates Inc. are listed as underwriters for the IPO.